This clinical trial is focused on studying the treatment of metastatic pancreatic adenocarcinoma, a type of cancer that has spread from the pancreas to other parts of the body. The study will explore the effectiveness and safety of a new treatment combination involving the investigational drug TTX-030 and chemotherapy, with or without the addition of another investigational drug called Budigalimab. The chemotherapy regimen includes two drugs: nab-paclitaxel and gemcitabine. These treatments will be compared to chemotherapy alone to see if the new combinations offer any additional benefits.

The purpose of this study is to evaluate whether adding TTX-030, with or without Budigalimab, to the standard chemotherapy regimen can improve outcomes for patients who have not received prior treatment for their metastatic pancreatic cancer. Participants in the study will be randomly assigned to one of three groups: one group will receive TTX-030 and chemotherapy, another group will receive TTX-030, Budigalimab, and chemotherapy, and the third group will receive only the chemotherapy. The study will monitor participants over a period of time to assess the progression of the disease and any side effects experienced.

Throughout the study, participants will receive their assigned treatments through intravenous infusion, which means the medication will be delivered directly into a vein. The study aims to provide valuable information on whether these new treatment combinations can help manage metastatic pancreatic cancer more effectively than the current standard chemotherapy alone. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the treatment’s impact on their cancer.